CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osim ...
Phase 2
Nashville, Tennessee, United States and 17 other locations
combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants.The main goals of this study are to:* E...
Phase 2
Nashville, Tennessee, United States and 32 other locations
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
Nashville, Tennessee, United States and 210 other locations
to assess the safety and tolerability of BMS-986525 alone and in combination with Nivolumab in participants with Relapsed/Refractory Small Cell Lung...
Phase 1, Phase 2
Nashville, Tennessee, United States and 10 other locations
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...
Phase 2
Nashville, Tennessee, United States and 123 other locations
locally advanced or metastatic disease.In addition, HER3-DXd will be evaluated in participants with locally advanced or metastatic NSCLC whose tumors...
Phase 1
Nashville, Tennessee, United States and 36 other locations
HCC is a common cancer worldwide and a leading cause of cancer-related death. Lung cancer is the most frequently ...
Phase 1
Nashville, Tennessee, United States and 21 other locations
in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung...
Phase 1, Phase 2
Nashville, Tennessee, United States and 58 other locations
This is an open-label study of NMS-03305293 with Temozolomide (TMZ) in patients with Small Cell Lung Cancer (SCLC). The aim of this...
Phase 1
Nashville, Tennessee, United States and 1 other location
is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors...
Phase 1, Phase 2
Nashville, Tennessee, United States and 14 other locations
Clinical trials
Research sites
Resources
Legal